StockData
Jazz Pharmaceuticals plc logo

Jazz Pharmaceuticals plc (JAZZ) stock

JAZZNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 2, 2026Score 7/30131% above fair value
$236.45−11.32 (-4.57%)

Close on Nov 19, 2026Market cap $15.35BP/E 77.0Yield –

Jazz Pharmaceuticals free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Jazz Pharmaceuticals's free cash flow for the twelve months ending Sep 30, 2026 was $1.62B, up 21.3% year over year. For fiscal 2025 it was $1.30B, down 4.5% from the year before. Over ten years it grew 10.1% a year on average. The highest annual figure on record is $1.36B in fiscal 2024.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025$1.30B-4.5%
FY2024Dec 31, 2024$1.36B+27.1%
FY2023Dec 31, 2023$1.07B-14.1%
FY2022Dec 31, 2022$1.24B+65.5%
FY2021Dec 31, 2021$750.87M-15.1%
FY2020Dec 31, 2020$884.64M+20.2%
FY2019Dec 31, 2019$736.27M-5.4%
FY2018Dec 31, 2018$778.53M+17.2%
FY2017Dec 31, 2017$664.14M+14.0%
FY2016Dec 31, 2016$582.70M+17.5%
FY2015Dec 31, 2015$495.99M+33.6%
FY2014Dec 31, 2014$371.26M+33.3%
FY2013Dec 31, 2013$278.46M+14.2%
FY2012Dec 31, 2012$243.78M+62.2%
FY2011Dec 31, 2011$150.32M+158.6%
FY2010Dec 31, 2010$58.14M–
FY2009Dec 31, 2009-$15.93M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$489.90M+6.6%
Q2 FY2026Jun 30, 2026$397.60M+423.8%
Q1 FY2026Mar 31, 2026$388.50M-6.6%
Q4 FY2025Dec 31, 2025$345.72M-10.3%
Q3 FY2025Sep 30, 2025$459.50M+18.4%
Q2 FY2025Jun 30, 2025$75.90M-76.6%
Q1 FY2025Mar 31, 2025$415.90M+59.8%
Q4 FY2024Dec 31, 2024$385.29M+145.0%
Q3 FY2024Sep 30, 2024$387.96M+28.1%
Q2 FY2024Jun 30, 2024$324.26M+11.4%
Q1 FY2024Mar 31, 2024$260.33M-17.8%
Q4 FY2023Dec 31, 2023$157.24M-52.7%
Q3 FY2023Sep 30, 2023$302.90M-28.4%
Q2 FY2023Jun 30, 2023$291.03M+0.1%
Q1 FY2023Mar 31, 2023$316.89M+61.1%
Q4 FY2022Dec 31, 2022$332.59M+98.2%
Q3 FY2022Sep 30, 2022$422.89M+59.1%
Q2 FY2022Jun 30, 2022$290.76M+742.4%
Q1 FY2022Mar 31, 2022$196.69M-30.5%
Q4 FY2021Dec 31, 2021$167.79M-7.9%
Q3 FY2021Sep 30, 2021$265.73M+4.4%
Q2 FY2021Jun 30, 2021$34.52M-80.8%
Q1 FY2021Mar 31, 2021$282.83M+5.5%
Q4 FY2020Dec 31, 2020$182.16M+125.8%
Q3 FY2020Sep 30, 2020$254.52M-22.0%
Q2 FY2020Jun 30, 2020$179.83M+33.3%
Q1 FY2020Mar 31, 2020$268.14M+38.0%
Q4 FY2019Dec 31, 2019$80.66M-62.1%
Q3 FY2019Sep 30, 2019$326.42M+50.1%
Q2 FY2019Jun 30, 2019$134.88M-28.2%
Q1 FY2019Mar 31, 2019$194.31M+21.3%
Q4 FY2018Dec 31, 2018$212.95M+8.8%
Q3 FY2018Sep 30, 2018$217.54M+20.5%
Q2 FY2018Jun 30, 2018$187.84M+48.0%
Q1 FY2018Mar 31, 2018$160.21M-0.5%
Q4 FY2017Dec 31, 2017$195.68M+9.1%
Q3 FY2017Sep 30, 2017$180.55M–
Q2 FY2017Jun 30, 2017$126.94M–
Q1 FY2017Mar 31, 2017$160.97M–
Q4 FY2016Dec 31, 2016$179.42M–

More Jazz Pharmaceuticals figures

See a number that looks wrong?